Cancer drug margins rebound despite 2019 price intervention
Seven years after the government first stepped in to curb excessive trade margins on cancer medicines, it is attempting another intervention. The latest move follows a push by the Supreme Court for the government to examine ways to rein in the cost of cancer treatment, including ...
















